Home
Partnering to accelerate antibiotic development and access to tackle drug-resistant bacterial infections
Nearly five million deaths are associated with antimicrobial resistance (AMR). Children and newborns are especially vulnerable to drug-resistant bacteria. 1 in 5 deaths caused by antibiotic resistance occur in children under the age of five, and up to 3 million newborns get serious infections that lead to life-threatening conditions every year.
Very few innovative new antibiotics have come to the market in the past years and resistance against these new agents develops faster than ever. There are many bottlenecks and challenges to the development, access and stewardship of new antibiotics to address the growing burden of drug-resistant infections, and especially those priority pathogens identified by the World Health Organization (WHO).
The symposium will serve to identify several of the bottlenecks to development, access, and stewardship and examine how partnerships that bring together the resources, expertise, and cooperation of the public, private, and not-for-profit sectors can best overcome these challenges and ensure the right antibiotic at the right time can reach patients in need.
Weitere Informationen finden Sie auf der Veranstaltungswebseite.
Registrieren können Sie sich hier.
